Page last updated: 2024-11-12

verruculogen

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

verruculogen: complex 6-O-methylindole cpd containing 3 nitrogens; induces tremor; tremorigenic metabolite from Penicillium verruculosum isolated from moldy peanuts; decreases GABA levels in CNS; structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

verruculogen : An organic heterohexacyclic compound that is a mycotoxic indole alkaloid isolated from Penicillium and Aspergillus species. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID13887805
CHEMBL ID551369
CHEBI ID72765
MeSH IDM0054536

Synonyms (23)

Synonym
CHEBI:72765 ,
(5r,10s,10ar,14as,15bs)-10,10a-dihydroxy-6-methoxy-2,2-dimethyl-5-(2-methylprop-1-en-1-yl)-1,10,10a,14,14a,15b-hexahydro-12h-3,4-dioxa-5a,11a,15a-triazacycloocta[1,2,3-lm]indeno[5,6-b]fluorene-11,15(2h,13h)-dione
5h,12h-3,4-dioxa-5a,11a,15a-triazacyclooct(lm)indeno(5,6-b)fluorene-11,15(2h,13h)-dione, 1,10,10a,14,14a,15b-hexahydro-10,10a-dihydroxy-7-methoxy-2,2-dimethyl-5-(2-methyl-1-propenyl)-, (5r,10s,10ar,14as,15bs)-
verruculogen
5h,12h-3,4-dioxa-5a,11a,15a-triazacyclooct(lm)indeno(5,6-b)fluorene-11,15(2h,13h)-dione, 1,10,10a,14,14a,15b-hexahydro-10,10a-dihydroxy-7-methoxy-2,2-dimethyl-5-(2-methyl-1-propenyl)-,(5r-(5-alpha,10-alpha,10a-alpha,14a-alpha-15b-alpha))-
(5r-(5alpha,10 alpha,10aalpha,14aalpha,15balpha))-1,10,10a,14,14a,15b-hexahydro-10,10a-dihydroxy-7-methoxy-2,2-dimethyl-5-(2-methyl-1-propenyl)-5h,12h-3,4-dioxa-5a,11a,15a-triaza cyclooct (1m) indeno (5,6-b)fluorene-11,15(2h,13h)-dione
TR1 ,
12771-72-1
C20045
tr 1
tr 1 toxin
AKOS030213151
J-005532
verruculogen, powder
CHEMBL551369
10,10a-dihydroxy-7-methoxy-2,2-dimethyl-5-(2-methylprop-1-en-1-yl)- 1,10,10a,14,14a,15b-hexahydro-5h,12h-3,4-dioxa-5a,11a,15a- triazacyclooct[lm]indeno[5,6-b]fluorene-11,15(2h,13h)-dione
tr toxin
(9r,14s,17s,23r,24s)-23,24-dihydroxy-5-methoxy-12,12-dimethyl-9-(2-methylprop-1-enyl)-10,11-dioxa-8,15,21-triazahexacyclo[12.10.1.02,7.08,25.015,23.017,21]pentacosa-1(25),2(7),3,5-tetraene-16,22-dione
4-methyl-4-(2-(4-nitro-n-phenylbenzamido)ethyl)morpholin-4-ium bromide
(5r,10s,10ar,14as,15bs)-10,10a-dihydroxy-7-methoxy-2,2-dimethyl-5-(2-methylprop-1-en-1-yl)-1,10,10a,12,13,14,14a,15b-octahydro-3,4-dioxa-5a,11a,15a-triazacycloocta[lm]indeno[5,6-b]fluorene-11,15(2h,5h)-dione
DTXSID30894030
5h,12h-3,4-dioxa-5a,11a,15a-triazacyclooct[lm]indeno[5,6-b]fluorene-11,15(2h,13h)-dione,1,10,10a,14,14a,15b-hexahydro-10,10a-dihydroxy-7-methoxy-2,2-dimethyl-5-(2-methyl-1-propenyl)-, (5r,10s,10ar,14as,15bs)-
8H5 ,

Research Excerpts

Overview

Verruculogen is a tremorgenic mycotoxin and contains an endoperoxide bond. It modifies the electrophysiological properties of HNEC.

ExcerptReferenceRelevance
"Verruculogen is a tremorgenic mycotoxin and contains an endoperoxide bond. "( FtmOx1, a non-heme Fe(II) and alpha-ketoglutarate-dependent dioxygenase, catalyses the endoperoxide formation of verruculogen in Aspergillus fumigatus.
Afiyatullov, S; Grundmann, A; Li, SM; Ruan, H; Steffan, N, 2009
)
2.01
"Verruculogen is a secondary metabolite that modifies the electrophysiological properties of HNEC. "( Verruculogen associated with Aspergillus fumigatus hyphae and conidia modifies the electrophysiological properties of human nasal epithelial cells.
Botterel, F; Bretagne, S; Cordonnier, C; Coste, A; Delaforge, M; Escudier, E; Khoufache, K; Loiseau, N; Puel, O; Rivollet, D, 2007
)
3.23

Actions

ExcerptReferenceRelevance
"Verruculogen was shown to cause a substantial increase (300-400%) in the miniature-end-plate potential (m.e.p.p.) frequency at the locust neuromuscular junction."( Actions of tremorgenic fungal toxins on neurotransmitter release.
Bradford, HF; De Belleroche, J; Mantle, PG; Norris, PJ; Penny, RH; Smith, CC; Thomas, AJ, 1980
)
0.98

Treatment

ExcerptReferenceRelevance
"Verruculogen pretreatment did not alter the veratrine-induced release of transmitter amino acids from cerebrocortex and spinal cord/medulla synaptosomes."( Actions of tremorgenic fungal toxins on neurotransmitter release.
Bradford, HF; De Belleroche, J; Mantle, PG; Norris, PJ; Penny, RH; Smith, CC; Thomas, AJ, 1980
)
0.98

Toxicity

ExcerptReferenceRelevance
" Verrucosidin appeared to have the highest toxic potential, testing positive in both assays."( Genotoxicity assessment of five tremorgenic mycotoxins (fumitremorgen B, paxilline, penitrem A, verruculogen, and verrucosidin) produced by molds isolated from fermented meats.
Fink-Gremmels, J; Nijmeijer, S; Sabater-Vilar, M, 2003
)
0.54

Dosage Studied

ExcerptRelevanceReference
" Repeated daily dosing of lambs and sheep for five days with P simplicissimum failed to enhance the effect, indicating that verruculogen toxicity was not cumulative."( A comparative study of sheep and pigs given the tremorgenic mycotoxins verruculogen and penitrem A.
Day, JB; Mantle, PG; Penny, RH; Peterson, DW, 1982
)
0.7
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (5)

RoleDescription
mycotoxinPoisonous substance produced by fungi.
potassium channel blockerAn agent that inhibits cell membrane glycoproteins that are selectively permeable to potassium ions.
GABA modulatorA substance that does not act as agonist or antagonist but does affect the gamma-aminobutyric acid receptor-ionophore complex. GABA-A receptors appear to have at least three allosteric sites at which modulators act: a site at which benzodiazepines act by increasing the opening frequency of gamma-aminobutyric acid-activated chloride channels; a site at which barbiturates act to prolong the duration of channel opening; and a site at which some steroids may act.
Aspergillus metaboliteAny fungal metabolite produced during a metabolic reaction in the mould, Aspergillus.
Penicillium metaboliteAny fungal metabolite produced during a metabolic reaction in Penicillium.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (5)

ClassDescription
indole alkaloidAn alkaloid containing an indole skeleton.
diolA compound that contains two hydroxy groups, generally assumed to be, but not necessarily, alcoholic. Aliphatic diols are also called glycols.
aromatic etherAny ether in which the oxygen is attached to at least one aryl substituent.
organic peroxideCompounds of structure ROOR' in which R and R' are organic groups.
organic heterohexacyclic compound
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (2)

PathwayProteinsCompounds
fumitremorgin A biosynthesis412
superpathway of fumitremorgin biosynthesis925

Bioassays (6)

Assay IDTitleYearJournalArticle
AID1336110Inhibition of BCRP in human K562 cells assessed as potentiation of SN38-mediated growth inhibition at 3 uM after 4 days by coulter counter method2016Bioorganic & medicinal chemistry letters, 12-15, Volume: 26, Issue:24
Biosynthetic approaches to creating bioactive fungal metabolites: Pathway engineering and activation of secondary metabolism.
AID1336103Cytotoxicity against human Jurkat cells2016Bioorganic & medicinal chemistry letters, 12-15, Volume: 26, Issue:24
Biosynthetic approaches to creating bioactive fungal metabolites: Pathway engineering and activation of secondary metabolism.
AID1336104Cytotoxicity against human HeLa cells2016Bioorganic & medicinal chemistry letters, 12-15, Volume: 26, Issue:24
Biosynthetic approaches to creating bioactive fungal metabolites: Pathway engineering and activation of secondary metabolism.
AID1336106Cytotoxicity against human HT-29 cells2016Bioorganic & medicinal chemistry letters, 12-15, Volume: 26, Issue:24
Biosynthetic approaches to creating bioactive fungal metabolites: Pathway engineering and activation of secondary metabolism.
AID1336111Inhibition of BCRP (unknown origin)-dependent ATPase activity at 50 uM after 30 mins by malachite green method2016Bioorganic & medicinal chemistry letters, 12-15, Volume: 26, Issue:24
Biosynthetic approaches to creating bioactive fungal metabolites: Pathway engineering and activation of secondary metabolism.
AID1336105Cytotoxicity against human MCF7 cells2016Bioorganic & medicinal chemistry letters, 12-15, Volume: 26, Issue:24
Biosynthetic approaches to creating bioactive fungal metabolites: Pathway engineering and activation of secondary metabolism.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (32)

TimeframeStudies, This Drug (%)All Drugs %
pre-199016 (50.00)18.7374
1990's1 (3.13)18.2507
2000's6 (18.75)29.6817
2010's8 (25.00)24.3611
2020's1 (3.13)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 26.25

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index26.25 (24.57)
Research Supply Index3.53 (2.92)
Research Growth Index5.10 (4.65)
Search Engine Demand Index29.35 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (26.25)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews3 (9.09%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other30 (90.91%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]